In Brief | Published:

Lupus nephritis: Phase III ocrelizumab trial halted by infections

Nature Reviews Rheumatology volume 9, page 444 (2013) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.


  1. 1.

    et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from the randomized, double-blind phase III BELONG study. Arthritis Rheum. doi:10.1002/art.38037

Download references

About this article

Publication history